HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF

HUTCHMED (China) Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026

$14.18+0.13 (+0.93%)

Close on Oct 19, 2026

Community

Notes and questions about HUTCHMED (China) from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in HUTCHMED (China)'s annual and quarterly filings with the SEC
Per-share figures adjusted for the 10-for-1 split on May 30, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HCM.

Revenue growth-13.0% · median 399.1%

Gross margin38.7% · median 56.9%

Operating margin-7.1% · median -31.5%

Net margin83.3% · median -41.9%

Advertisement
300 × 250